Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Advances review identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://thenewpainkillerconolidin79901.aboutyoublog.com/47800637/the-2-minute-rule-for-conolidin-to-replace-traditional-painkillers